A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Shin, Vivian Yvonne ^a   Ng, Enders K O ^a   Chan, Vivian W ^a   Kwong, Ava ^a,b,c   Chu, Kent Man ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^c SAR   (Hong Kong)

Author keywords

Circulating microRNA; Diagnostic marker; Gastric cancer

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 140 5P; MICRORNA 18A; MICRORNA 199A 3P; MICRORNA 627; MICRORNA 629; MICRORNA 652; UNCLASSIFIED DRUG; MIRN627 MICRORNA, HUMAN; MIRN629 MICRORNA, HUMAN; MIRN652 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; UPREGULATION; VALIDATION PROCESS; AGED; BLOOD; CASE CONTROL STUDY; DISEASE COURSE; EARLY CANCER DIAGNOSIS; MIDDLE AGED; STOMACH NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; ROC CURVE; STOMACH NEOPLASMS;

EID: 84961167411     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0473-3     Document Type: Article

References (23)

1. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125:666-73.
2. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer. 2000;88:921-32.
3. Xia HH, Yang Y, Chu KM, Gu Q, Zhang YY, He H, et al. Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. Cancer. 2009;115:5441-9.
4. Chan AO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, et al. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut. 2001;48:808-11.
5. Chan AO, Chu KM, Lam SK, Cheung KL, Law S, Kwok KF, et al. Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. Cancer. 2005;104:740-6.
6. Caldas C, Brenton JD. Sizing up miRNAs as cancer genes. Nat Med. 2005;11:712-4.
7. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005;37:766-70.
8. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 2005;120:21-4.
9. Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, et al. Prognostic Significance of miR-215 in Colon Cancer. Clin Colorectal Cancer. 2011;10:340-7.
10. Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat. 2009;117:131-40.
11. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 2009;28:3526-36.
12. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58:1375-81.
13. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997-1006.
14. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513-8.
15. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257-61.
16. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-69.
17. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010;102:1174-9.
18. Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W, et al. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest. 2008;88:1358-66.
19. Shin VY, Jin H, Ng EK, Cheng AS, Chong WW, Wong CY, et al. NF-kappaB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors. Carcinogenesis. 2011;32:240-5.
20. Lulla RR, Costa FF, Bischof JM, Chou PM, de F Bonaldo M, Vanin EF, et al. Identification of Differentially Expressed MicroRNAs in Osteosarcoma. Sarcoma. 2011;2011:732690.
21. Sukata T, Sumida K, Kushida M, Ogata K, Miyata K, Yabushita S, et al. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett. 2011;200:46-52.
22. Lai CY, Yu SL, Hsieh MH, Chen CH, Chen HY, Wen CC, et al. MicroRNA Expression Aberration as Potential Peripheral Blood Biomarkers for Schizophrenia. PLoS One. 2011;6:e21635.
23. Gao W, Shen H, Liu L, Xu J, Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol. 2011;137:557-66.